Showing results (51-60 of 58) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 58 results.
International Journal of Clinical Oncology|October 2, 2021
Deferred radical prostatectomy in patients who initially elected for active surveillance: a multi-institutional, prospective, observational cohort of the PRIAS-JAPAN studyYoichiro Tohi, Takuma Kato, Masaki Nakamura, et al.
Japanese Journal of Clinical Oncology|July 27, 2023
Increasing age predicts adverse pathology including intraductal carcinoma of the prostate and cribriform patterns in deferred radical prostatectomy after upfront active surveillance for Gleason grade group 1 prostate cancer: analysis of prospective observational study cohortYoichiro Tohi, Ryou Ishikawa, Takuma Kato, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|December 22, 2025
Clinical Features and Risk Factors of Enfortumab Vedotin-Induced Peripheral Neuropathy in Patients With Metastatic Urothelial Carcinoma: A Multicenter Retrospective Study (YUSHIMA Study)Takahiko Soma, Hajime Tanaka, Yuki Nakamura, et al.
International Journal of Clinical Oncology|December 6, 2022
Clinical outcomes of intraductal carcinoma or cribriform in radical prostatectomy specimens of men opting for active surveillance: data from the PRIAS-JAPAN studyYoichiro Tohi, Ryou Ishikawa, Takuma Kato, et al.
Japanese Journal of Clinical Oncology|January 28, 2026
Real-world efficacy of enfortumab vedotin in Japanese patients with metastatic urothelial carcinoma stratified by EV-301 trial eligibility: a multicenter Bayesian restricted mean survival time analysisShugo Yajima, Soichiro Yoshida, Wei Chen, et al.
Japanese Journal of Clinical Oncology|June 6, 2022
Impact of adherence to criteria on oncological outcomes of radical prostatectomy in patients opting for active surveillance: data from the PRIAS-JAPAN studyYoichiro Tohi, Takuma Kato, Jimpei Miyakawa, et al.
BMC Cancer|March 12, 2021
Non-maintenance intravesical Bacillus Calmette-Guérin induction therapy with eight doses in patients with high- or highest-risk non-muscle invasive bladder cancer: a retrospective non-randomized comparative studyMakito Miyake, Kota Iida, Nobutaka Nishimura, et al.
BMC Urology|March 6, 2023
A phase II randomized trial of metastasis-directed therapy with alpha emitter radium-223 in men with oligometastatic castration-resistant prostate cancer (MEDAL)Soichiro Yoshida, Taro Takahara, Yuki Arita, et al.
Pageof 6